Physician profile
David A Marcoux
NPI 1730140864
$1,972.14
in general payments reported to CMS, 2019-2025
28 companies · $540 in 2025
The $540 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $202 · 2020: $15.58 · 2021: $225 · 2022: $200 · 2023: $364 · 2024: $426 · 2025: $540.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,155 · Consulting Fee: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,154.57 |
| Consulting Fee | $175.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $344.14 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $243.67 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $191.70 | 2024-2025 | Prolia, Prolia, Evenity |
| Pfizer INC. | $165.20 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $144.26 | 2022-2025 | Xifaxan, Trulance |
| Glaxosmithkline, LLC. | $108.90 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Novo Nordisk INC | $87.52 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $84.48 | 2021-2025 | Mounjaro, Kisunla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.42 | 2022-2024 | Ofev |
| Lundbeck LLC | $57.39 | 2023 | Rexulti |
| Exact Sciences Corporation | $48.75 | 2024-2025 | Cologuard Collection Kit |
| Mylan Specialty L.P. | $48.55 | 2023-2024 | Yupelri |
| Antares Pharma, INC. | $45.68 | 2025 | Xyosted |
| E.R. Squibb & Sons, L.L.C. | $33.89 | 2019-2024 | Eliquis |
| Alnylam Pharmaceuticals INC. | $33.31 | 2022-2024 | Onpattro |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $30.19 | 2024-2025 | Freestyle Libre 3 |
| Xeris Pharmaceuticals, INC. | $27.99 | 2021-2022 | |
| Strongbridge US INC. | $26.43 | 2019 | |
| Corcept Therapeutics | $23.38 | 2024 | Korlym |
| Allergan, INC. | $23.24 | 2019 | |
| Sunovion Pharmaceuticals INC. | $21.37 | 2022 | |
| Sanofi-Aventis U.S. LLC | $19.44 | 2019 | |
| Sumitomo Pharma America, INC. | $18.13 | 2024 | Gemtesa |
| Aimmune Therapeutics, INC. | $17.30 | 2025 | Vowst |
| Astellas Pharma US INC | $17.03 | 2023 | Veozah |
| Merck Sharp & Dohme LLC | $16.31 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.19 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $13.28 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Marcoux listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.